# Absci climbs after New Outperform at Leerink on catalyst path.Absci outlines ABS-201 interim 13-week data in H2 2026.

*biotech · news · 2026-06-05 · FinanzNachrichten*

## Key points

- Veru shares rose after announcing a collaboration with Novo Nordisk.
- Health Catalyst gained following the divestment of its revenue workflow and analytics software business.
- Absci shares climbed after Leerink assigned a new Outperform rating, citing its catalyst path.
- Alvotech has resubmitted its Biologics License Applications (BLAs) to the FDA.

05:00Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesenDoAbsci climbs after New Outperform at Leerink on catalyst path08.05.Absci outlines ABS-201 interim 13-week data in H2 2026 while adding ABS-202 and funding plans into H1 202805:00Top Biotech Gainers: VERU Teams Up With NVO, ABSI On Watch, ALVO Resubmits BLAs To FDA...REYKJAVIK (dpa-AFX) - Thursday's top gainers include Veru, following a Novo Nordisk collaboration; Health Catalyst, following a divestment of its revenue workflow and analytics software business... ► Artikel lesen

**Companies:** Novo Nordisk, Veru, Health Catalyst, Absci
**Countries:** Iceland

[Read the full story on FinanzNachrichten](https://www.finanznachrichten.de/nachrichten-2026-06/68686977-top-biotech-gainers-veru-teams-up-with-nvo-absi-on-watch-alvo-resubmits-blas-to-fda-020.htm)

---

Canonical: https://newsio.io/n/78943deb-d8de-4754-bdf0-b1c39b0c26e0/absci-climbs-after-new-outperform-at-leerink-on-catalyst-path-absci-outlines-abs
Summarized by Newsio from FinanzNachrichten. https://newsio.io/how-it-works